NASDAQ:UPB Upstream Bio Q1 2025 Earnings Report $4.82 -0.22 (-4.27%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Upstream Bio EPS ResultsActual EPS-$0.51Consensus EPS -$0.49Beat/MissMissed by -$0.02One Year Ago EPSN/AUpstream Bio Revenue ResultsActual Revenue$0.57 millionExpected Revenue$0.71 millionBeat/MissMissed by -$140.00 thousandYoY Revenue GrowthN/AUpstream Bio Announcement DetailsQuarterQ1 2025Date5/6/2025TimeBefore Market OpensConference Call DateTuesday, May 6, 2025Conference Call Time7:00AM ETUpcoming EarningsUpstream Bio's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Upstream Bio Earnings HeadlinesHead to Head Analysis: Upstream Bio (NASDAQ:UPB) & Aclaris Therapeutics (NASDAQ:ACRS)September 28, 2026 | americanbankingnews.comUpstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly DosingSeptember 8, 2026 | quiverquant.comQMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.October 5 at 1:00 AM | Paradigm Press (Ad)Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026September 8, 2026 | globenewswire.comAnalysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)September 2, 2026 | theglobeandmail.comUpstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027September 1, 2026 | finance.yahoo.comSee More Upstream Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email. Email Address About Upstream BioUpstream Bio (NASDAQ:UPB) is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. The company’s research is centered on targeting biological pathways involved in immune-system activation and chronic inflammation, with an emphasis on conditions affecting the airways. Upstream Bio’s lead product candidate is verekitug, formerly known as UPB-101. Verekitug is a long-acting monoclonal antibody designed to selectively inhibit thymic stromal lymphopoietin, or TSLP, a cytokine that contributes to the development and persistence of inflammation. The company is evaluating verekitug as a potential treatment for inflammatory respiratory conditions, including asthma and chronic rhinosinusitis with nasal polyps. Upstream Bio advances its programs through clinical development and collaborations with research and healthcare organizations. The company is based in the United States and focuses on serving patients with significant unmet needs in immune-mediated and inflammatory diseases. As a clinical-stage biotechnology company, its operations remain primarily centered on research, clinical trials and the development of potential future therapies.View Upstream Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
